Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Via Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

There's a lot of excitement around the new insights that vulnerable plaque, a certain kind of inflammatory plaque, is the culprit in myocardial infarction, but so far, no one has figured out how to treat it. Thomas Quertermous of Stanford has identified inflammatory pathways that contribute to atherosclerosis and Via Pharmaceuticals was formed to develop a drug, already tested extensively in humans, that emanated from his research program.

You may also be interested in...



Start-Up Previews (10/2007)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.

Cardiovascular Drug Start-Ups

The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.

Cardiovascular Drug Start-Ups

The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel